Ocular Therapeutix (OCUL) Reports Q4 Revenues Below Estimates

Note: EPS may not be comparable

Ocular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of $, versus ($0.52) reported last year. Revenue for the quarter came in at $487 thousand versus the consensus estimate of $520 thousand.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• Hillman Solutions launches $1.1B debt refinancing, reports Q2 sales
• Agenus rises premarket; Micron, Western Digital slide
• WD-40 Co. (WDFC) Tops Q3 EPS by 76c; offers guidance